Stem Cell Research Institute's domestic market share exceeds 90%
First written in FY2017-Q1. 5 of 11 entries say "Raised", first in FY2017. Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「StemCell Institute operates a cell-banking business based on cells derived from perinatal tissues, including cord blood and umbilical cords, for regenerative medicine and cell therapy. It is also developing new treatments and regenerative medicine products using these cells, as well as developing and investing in businesses in areas including regenerative medicine, fertility treatment, childbirth and child-rearing on the basis of these business platforms. The company is Japan's largest private cord blood bank, with approximately 99% of the total domestic cord blood storage market.」
The company reconfirms its business development based on cell banking for cord blood and umbilical cords, as well as its approximately 99% domestic share. - FY2023-Q1RaisedAnnual report
「In its regenerative medicine-related business, StemCell Institute, a private cord blood bank with a 99% domestic share listed on the TSE Growth Market under securities code 7096, is working under the slogan "New medical options for new life" to contribute to opening up new avenues in healthcare.」
StemCell Institute's domestic share is stated at 99%, a higher rounded figure than the previous 98.8% based on total units in storage. - FY2021RaisedAnnual report
「As of the end of March 2021, the company stored 58,069 of the 58,796 samples stored in Japan, according to the Ministry of Health, Labour and Welfare's Health Insurance Bureau report, "Report on Cord Blood Transfer Results, etc." This represents a 98.8% share, making it Japan's largest private cord blood bank.」
The domestic share based on total units in storage increased from the previously disclosed 98.6% to 98.8%. - FY2020Disclosure of share based on total units in storageAnnual report
「As of the end of March 2019, the company accounted for 50,406 of the 51,127 total units in storage, or a 98.6% share, according to the Ministry of Health, Labour and Welfare's Health Insurance Bureau report, "Report on Cord Blood Transfer Results, etc." It is Japan's largest private cord blood bank.」
Unlike the previous approximately 99% share based on new annual storage, the company reported a 98.6% share based on total units in storage. - FY2019-Q3RestatedAnnual report
「StemCell Institute, which operates Japan's largest cord blood bank in the advanced medical treatment field, with approximately 99% of the share of new storage customers, continued to see strong growth in new storage, with revenue up 31.3% year on year and operating profit up 93.4%.」
The company reconfirms the fact that StemCell Institute holds approximately 99% of the share of new storage contracts. - FY2018-Q3RaisedAnnual report
「StemCell Institute, which operates a private cord blood bank, was publicly reported to hold approximately 99% of the domestic share of total stored units, based on new annual storage, according to a survey conducted in September last year by the Health Policy Bureau of the Ministry of Health, Labour and Welfare.」
The company cites the higher figure of approximately 99% for domestic market share, while explicitly stating that this is based on new annual storage. - FY2018-Q2RaisedAnnual report
「StemCell Institute, which holds approximately 96% of the domestic private cord blood banking market, continues to achieve steady growth in business performance.」
StemCell Institute's domestic market share is stated at approximately 96%, up from the previous approximately 95%. - FY2018-Q1RestatedAnnual report
「StemCell Institute, which holds approximately 95% of the domestic market, had 41,128 people with stored samples as of the end of June this year, continuing its steady growth.」
The company reiterates the fact that StemCell Institute holds approximately 95% of the domestic market. - FY2017RaisedAnnual report
「StemCell Institute, which holds approximately 95% of the domestic market, operates a long-term storage business for cord blood-derived stem cells for regenerative medicine, cell therapy and the treatment of intractable blood diseases.」
StemCell Institute's domestic market share is stated at the higher level of approximately 95%, up from the previous approximately 90%. - FY2017-Q2RestatedAnnual report
「StemCell Institute, which provides long-term storage of umbilical cord blood-derived stem cells for regenerative and cell therapies and the treatment of intractable hematological diseases, currently holds approximately 90% of the domestic market.」
The company reiterates the structural fact that StemCell Institute holds approximately 90% of the domestic market. - FY2017-Q1First statedAnnual report
「StemCell Institute, which holds more than 90% of the domestic market, primarily provides long-term storage services for cord blood-derived stem cells in preparation for future diseases, regenerative medicine and cell therapy.」
The company identifies StemCell Institute's long-term storage of cord blood-derived stem cells as its core business and states that it holds more than 90% of the domestic market.